Navigation Links
PRA Opens Office in Singapore
Date:2/23/2012

RALEIGH, N.C., Feb. 23, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, continues our expansion across the burgeoning Asia-Pacific region with the recent opening of an office in Singapore. The office will serve as PRA's central clinical operations location for the region, strengthening the quality and timeliness of our deliverables to sponsors.

The Singapore facility, conveniently located in the heart of the city-state, will provide monitoring, project management, safety reporting, feasibility and other services.

"Building our capability across the region with the center in Singapore permits our sponsors to experience a wider range of services and expertise," said Helen Neal, PRA's Director of Clinical Operations for Asia-Pacific. "This location provides our teams with access to experts and resources within their time zone, positively impacting our speed and quality of delivery on projects."

Geographically renowned as the region's pharmaceutical and biomedical center, Singapore is the ideal location from which to deliver centralized study support to the region. This city-state serves as an excellent logistics hub with high fluency rates in English, and its government strongly promotes and encourages CROs to conduct cutting-edge clinical research.

"Opening a Singapore office for PRA is an exciting and significant milestone in the company's evolution and is evidence that PRA acknowledges and embraces the full potential that the Asia-Pacific region can bring to the global business going forward," said Ms. Neal.

PRA has been strategically expanding our Asia-Pacific operations since 2000. In addition to Singapore, PRA operates in eight other countries within the region: Korea, Taiwan, China, Hong Kong, Thailand, Australia, New Zealand, and India.

About PRA   

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stevenage Bioscience Catalyst Opens With Exciting Year Ahead
2. Alchem International Opens Sales and Marketing Office in the U.S.
3. CoreLab Partners Opens Office in Tokyo, Japan
4. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
5. Golden Seeds Opens Office in PLSG Incubator
6. MIABE standard opens up new opportunities in drug discovery
7. Medical Malpractice Insurance Company- Healthcare Providers Insurance Exchange (HPIX) has Expanded its Presence in New Jersey, Opens New Office
8. "Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use
9. New England Biolabs Opens New Subsidiary Office in France
10. New beamline at MAX II opens for research
11. Discovery opens the door to electricity from microbes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/24/2017)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing ... Leader event to highlight new clinical data that will ... the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company,s ... in-person and via live webcast on Tuesday, February 28 ... the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):